Evrysdi® (risdiplam) has received expanded approval to treat spinal muscular atrophy (SMA) in patients of all ages. It was previously indicated for patients two months of age and older.

• SMA is a rare, progressive neuromuscular disorder that can affect a person’s ability to walk, eat, and breathe. Evrysdi, made by Genentech, first received FDA approval to treat SMA in 2020.
• Under the recommended dosing, Evrysdi should be given via oral syringe once daily after a meal. The dosage strength is based on the patient’s age and body weight:
  • Less than two months old:15mg/kg
  • Two months to less than two years old: 0.2mg/kg
  • At least two years old and weighing less than 20kg: 0.25mg/kg
  • At least two years old and weighing at least 20kg: 5mg